Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment

Journal of Alzheimer's Disease

Volumn 19, Issue 1, 2010, Pages 353-372

  Smith, Mark A ^a   Zhu, Xiongwei ^a   Tabaton, Massimo ^b   Liu, Gang ^c   McKeel Jr , Daniel W ^d   Cohen, Mark L ^a   Wang, Xinglong ^a   Siedlak, Sandra L ^a   Dwyer, Barney E ^i,j   Hayashi, Takaaki ^e   Nakamura, Masao ^f   Nunomura, Akihiko ^g   Perry, George ^a,h  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOKKAIDO INSTITUTE OF PUBLIC HEALTH   (Japan)

^f ASAHIKAWA MEDICAL COLLEGE   (Japan)

^g UNIVERSITY OF YAMANASHI   (Japan)

^h University of San Antonio   (United States)

ⁱ VA MEDICAL CENTER   (United States)

^j DARTMOUTH MEDICAL SCHOOL   (United States)

more..

Author keywords

Alzheimer's disease; Chelator; Diagnostic; Free radicals; Iron; Mild cognitive impairment (MCI); Oxidative stress; Pre clinical; Redox activity

Indexed keywords

AMYLOID BETA PROTEIN; CHELATING AGENT; FREE RADICAL; IRON;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; HISTOCHEMISTRY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PURKINJE CELL; ANIMAL; BRAIN; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; REVIEW; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION DISORDERS; FREE RADICALS; HUMANS; IRON; OXIDATIVE STRESS; UP-REGULATION;

EID: 75149152568     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1239     Document Type: Article

References (88)

1. Smith MA (1998) Alzheimer disease. Int Rev Neurobiol 42, 1-54.
2. Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol (Berl) 111, 503-509.
3. Hardy J (2006) Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 9, 151-153.
4. Lee VM, Trojanowski JQ (2006) Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. J Alzheimers Dis 9, 257-262.
5. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA (2005) Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 11, 164-169.
6. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 3, 75-80.
7. Smith MA, Casadesus G, Joseph JA, Perry G (2002) Amyloidbeta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 33, 1194-1199.
8. Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G, Nakamura M (2007) Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med 43, 1552-1559.
9. Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Hayashi Y, Nakayama K, Hayashi T (2007) Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry (Mosc) 46, 12737-12743.
10. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21, 3017-3023.
11. Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szweda LI, Aliev G, Smith MA, Zhu X, Perry G (2007) Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol 66, 525-532. (Pubitemid 46869694)
12. Reddy PH, Beal MF (2005) Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev 49, 618-632.
13. Wang X, Su B, Fujioka H, Zhu X (2008) Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol 173, 470-482.
14. Avila J (2006) Tau protein, the main component of paired helical filaments. J Alzheimers Dis 9, 171-175.
15. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA (1997) Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 150, 1933-1939.
16. Bowser R, Smith MA (2002) Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle. J Alzheimers Dis 4, 249-254.
17. McShea A, Wahl AF, Smith MA (1999) Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. Med Hypotheses 52, 525-527.
18. Perry G, Nunomura A, Raina AK, Aliev G, Siedlak SL, Harris PL, Casadesus G, Petersen RB, Bligh-Glover W, Balraj E, Petot GJ, Smith MA (2003) A metabolic basis for Alzheimer disease. Neurochem Res 28, 1549-1552.
19. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, Perry G (1998) Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4- dinitrophenylhydrazine. J Histochem Cytochem 46, 731-735.
20. Smith MA, Rudnicka-Nawrot M, Richey PL, Praprotnik D, Mulvihill P, Miller CA, Sayre LM, Perry G (1995) Carbonylrelated posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 64, 2660-2666.
21. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68, 2092-2097.
22. Nunomura A, Perry G, Pappolla MA,Wade R, Hirai K, Chiba S, Smith MA (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19, 1959-1964. (Pubitemid 29133374)
23. Castellani RJ, Harris PL, Sayre LM, Fujii J, Taniguchi N,Vitek MP, Founds H, Atwood CS, Perry G, Smith MA (2001) Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 31, 175-180.
24. Mattson MP, Carney JW, Butterfield DA (1995) A tombstone in Alzheimer's? Nature 373, 481.
25. Smith MA, Sayre LM,VitekMP, Monnier VM, PerryG(1995) Early AGEing and Alzheimer's. Nature 374, 316.
26. Smith MA (2006) Oxidative stress and iron imbalance in Alzheimer disease: how rust became the fuss! J Alzheimers Dis 9, 305-308.
27. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H,Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, SmithMA(2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767.
28. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F, Piombo G, Perry G, Smith M, Traverso N, Tabaton M (1998) Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 243, 849-851.
29. Mecocci P (2004) Oxidative stress in mild cognitive impairment and Alzheimer disease: a continuum. J Alzheimers Dis 6, 159-163.
30. Keller JN, Schmitt FA, Scheff SW, Ding Q, ChenQ, Butterfield DA, Markesbery WR (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156.
31. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24, 915-919.
32. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, Nucciarone B, Siciliano G (2005) Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26, 567-573.
33. Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, Arvanitakis Z (2006) Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 27, 252-261.
34. Lovell MA, Markesbery WR(2007) Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 85, 3036-3040.
35. Butterfield DA, Sultana R (2007) Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the pro gression of this dementing disorder. J Alzheimers Dis 12, 61-72.
36. Grant WB (1999) Dietary links to Alzheimer's disease: 1999 update. J Alzheimers Dis 1, 197-201.
37. Smith MA, Petot GJ, Perry G (1999) Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. J Alzheimers Dis 1, 203-206.
38. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94, 9866-9868.
39. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, SmithMA (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74, 270-279.
40. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52.
41. Lavados M, Guillon M, Mujica MC, Rojo LE, Fuentes P, Maccioni RB (2008) Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. J Alzheimers Dis 13, 225-232.
42. Kala SV, Hasinoff BB, Richardson JS (1996) Brain samples from Alzheimer's patients have elevated levels of loosely bound iron. Int J Neurosci 86, 263-269.
43. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368.
44. Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW, Jr., Rubin EH, Morris JC (2001) Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 56, 361-367.
45. Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412-2414.
46. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, Raina AK, Vinters HV, Tabaton M, Johnson AB, Paula- Barbosa M, Avila J, Jones PK, Castellani RJ, Smith MA, Perry G (2003) Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 162, 1623-1627.
47. Siedlak SL, Casadesus G,Webber KM, Pappolla MA, Atwood CS, Smith MA, Perry G (2009) Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic Res 43, 156-164.
48. Zhu X, Lee HG, Perry G, SmithMA(2007) Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 1772, 494-502.
49. Zhu X, Raina AK, Perry G, Smith MA (2004) Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3, 219-226.
50. Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G (2007) Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 12, 195-206.
51. Mecocci P, Cherubini A, Polidori MC, Cecchetti R, Chionne F, SeninU(1998) Oxidative stress and lymphocytes in Alzheimer disease. Arch Gerontol Geriatr 26 (Suppl 1), 313-316.
52. Premkumar DR, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN (1995) Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 65, 1399-1402.
53. SmithMA,Kutty RK, Richey PL,Yan SD, Stern D,Chader GJ, Wiggert B, Petersen RB, Perry G (1994) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145, 42-47.
54. Schipper HM, Cisse S, Stopa EG (1995) Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 37, 758-768.
55. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ (1992) Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 31, 327-335.
56. Smith MA, Wehr K, Harris PL, Siedlak SL, Connor JR, Perry G (1998) Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res 788, 232-236.
57. Perry G, Nunomura A, Hirai K, Takeda A, Aliev G, Smith MA (2000) Oxidative damage in Alzheimer's disease: the metabolic dimension. Int J Dev Neurosci 18, 417-421. (Pubitemid 30243071)
58. Blass JP, Sheu KF, Piacentini S, Sorbi S (1997) Inherent abnormalities in oxidative metabolism in Alzheimer's disease: interaction with vascular abnormalities. Ann N Y Acad Sci 826, 382-385.
59. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11, 721-736.
60. Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G (1999) Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys 370, 236-239.
61. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, Casadesus G, Zhu X (2008) Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 105, 19318-19323.
62. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334, 752-758.
63. Matthews PM (2007) Molecular imaging of brain amyloid in mild cognitive impairment and Alzheimer's disease. Nat Clin Pract Neurol 3, 366-367.
64. Small GW (1996) Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease. J Clin Psychiatry 57 Suppl 14, 9-13.
65. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP,Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24, 10191-10200.
66. Sayre LM, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8, 721-738.
67. Perry G, Nunomura A, Hirai K, Zhu X, Perez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM, Takeda A, Smith MA (2002) Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med 33, 1475-1479. (Pubitemid 35351590)
68. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, et al. (1995) Nonenzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1, 693-699.
69. Castellani RJ, Lee HG, Perry G, SmithMA(2006) Antioxidant protection and neurodegenerative disease: the role of amyloidbeta and tau. Am J Alzheimers Dis Other Demen 21, 126-130.
70. Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S, Danni O, Parola M, Smith MA, Perry G, Tamagno E, Tabaton M (2009) The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem 108, 1045-1056.
71. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10, 279-288.
72. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M (2008) Oxidative stress activates a positive feedback between the gamma- and betasecretase cleavages of the beta-amyloid precursor protein. J Neurochem 104, 683-695.
73. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30, 447-450.
74. Atwood CS, Robinson SR, Smith MA (2002) Amyloid-beta: redox-metal chelator and antioxidant. J Alzheimers Dis 4, 203-214.
75. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI (2000) Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 275, 19439-19442.
76. McKeel Jr. DW, Burns JM, Meuser TM, Morris JC (2007) Neuropathology of preclinical and clinical Alzheimer's disease In Dementia: an Atlas of Investigation and Diagnosis, McKeel Jr. DW, Burns JM, Meuser TM, Morris JC, eds. Clinical Publishing, Oxford, UK, pp. 71-94.
77. Bertoni-Freddari C, Fattoretti P, Solazzi M, Giorgetti B, Di Stefano G, Casoli T, Meier-Ruge W (2003) Neuronal death versus synaptic pathology in Alzheimer's disease. Ann N Y Acad Sci 1010, 635-638.
78. Bertoni-Freddari C, Fattoretti P, Paoloni R, Caselli U, Meier- Ruge W (1997) Impaired dynamic morphology of cerebellar mitochondria in physiological aging and Alzheimer's disease. Ann N Y Acad Sci 826, 479-482.
79. Thomann PA, Schlafer C, Seidl U, Santos VD, Essig M, Schroder J (2008) The cerebellum in mild cognitive impairment and Alzheimer's disease - a structural MRI study. J Psychiatr Res 42, 1198-1202.
80. Wang J, Markesbery WR, Lovell MA (2006) Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 96, 825-832.
81. Ghanbari HA, Ghanbari K, Harris PL, Jones PK, Kubat Z, Castellani RJ, Wolozin BL, Smith MA, Perry G (2004) Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell 3, 41-44.
82. Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, Rinaldi P, Cecchetti R, Stahl W, Senin U, Beal MF (2002) Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 59, 794-798.
83. Liu G, Men P, Kudo W, Perry G, Smith MA (2009) Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease. Neurosci Lett 455, 187-190.
84. Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, Zhu X (2007) Iron: the Redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 32, 1640-1645.
85. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA (2006) Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 406, 189-193.
86. Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA (2005) Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 1741, 246-252.
87. Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S (2008) Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 22, 1296-1305.
88. Bush AI (2008) Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 15, 223-240.